FR2946340B1 - Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. - Google Patents

Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.

Info

Publication number
FR2946340B1
FR2946340B1 FR0953752A FR0953752A FR2946340B1 FR 2946340 B1 FR2946340 B1 FR 2946340B1 FR 0953752 A FR0953752 A FR 0953752A FR 0953752 A FR0953752 A FR 0953752A FR 2946340 B1 FR2946340 B1 FR 2946340B1
Authority
FR
France
Prior art keywords
acetamia
inhibitors
phenyl
pharmaceutical
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0953752A
Other languages
English (en)
Other versions
FR2946340A1 (fr
Inventor
Cedric Poinsard
Thibaud Portal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR0953752A priority Critical patent/FR2946340B1/fr
Priority to EP10705166A priority patent/EP2401259A1/fr
Priority to US13/202,732 priority patent/US8420682B2/en
Priority to PCT/EP2010/052494 priority patent/WO2010097464A1/fr
Priority to CA2751327A priority patent/CA2751327A1/fr
Priority to JP2011551493A priority patent/JP2012518675A/ja
Publication of FR2946340A1 publication Critical patent/FR2946340A1/fr
Application granted granted Critical
Publication of FR2946340B1 publication Critical patent/FR2946340B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Birds (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
FR0953752A 2009-02-26 2009-06-05 Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. Expired - Fee Related FR2946340B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0953752A FR2946340B1 (fr) 2009-06-05 2009-06-05 Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
EP10705166A EP2401259A1 (fr) 2009-02-26 2010-02-26 Nouveaux dérivés de n-phénylacétamide, qui inhibent l'enzyme soat-1, et compositions pharmaceutiques et cosmétiques contenant ceux-ci
US13/202,732 US8420682B2 (en) 2009-02-26 2010-02-26 N-phenylacetamide derivatives, which inhibit the enzyme SOAT-1, and pharmaceutical and cosmetic compositions containing them
PCT/EP2010/052494 WO2010097464A1 (fr) 2009-02-26 2010-02-26 Nouveaux dérivés de n-phénylacétamide, qui inhibent l'enzyme soat-1, et compositions pharmaceutiques et cosmétiques contenant ceux-ci
CA2751327A CA2751327A1 (fr) 2009-02-26 2010-02-26 Nouveaux derives de n-phenylacetamide, qui inhibent l'enzyme soat-1, et compositions pharmaceutiques et cosmetiques contenant ceux-ci
JP2011551493A JP2012518675A (ja) 2009-02-26 2010-02-26 酵素ｓｏａｔ−１を阻害する新規ｎ−フェニルアセトアミド誘導体並びにこれらを含む医薬組成物及び化粧品組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0953752A FR2946340B1 (fr) 2009-06-05 2009-06-05 Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.

Publications (2)

Publication Number Publication Date
FR2946340A1 FR2946340A1 (fr) 2010-12-10
FR2946340B1 true FR2946340B1 (fr) 2011-06-24

Family

ID=41202447

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0953752A Expired - Fee Related FR2946340B1 (fr) 2009-02-26 2009-06-05 Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.

Country Status (6)

Country Link
US (1) US8420682B2 (fr)
EP (1) EP2401259A1 (fr)
JP (1) JP2012518675A (fr)
CA (1) CA2751327A1 (fr)
FR (1) FR2946340B1 (fr)
WO (1) WO2010097464A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2946345B1 (fr) * 2009-06-05 2011-05-20 Galderma Res & Dev Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
FR2946346B1 (fr) * 2009-06-05 2011-05-20 Galderma Res & Dev Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
FR2946341B1 (fr) * 2009-06-05 2011-06-24 Galderma Res & Dev Nouveaux derives de n-phenyl acetamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1032258B (de) 1956-12-20 1958-06-19 Kali Chemie Ag Verfahren zur Herstellung von in 5-Stellung mono- und disubstituierten 1-Aryl-hydantoinen
US5003106A (en) 1983-07-19 1991-03-26 American Cyanamid Company Antiatherosclerotic ureas and thioureas
US4623663A (en) 1985-12-23 1986-11-18 Warner-Lambert Company Non-steroidal anti-inflammatory compounds and compositions thereof
IE61716B1 (en) 1987-06-02 1994-11-30 Warner Lambert Co Antihyperlipidemic and antiatherosclerotic urea compounds
GB8827152D0 (en) 1988-11-21 1988-12-29 Wellcome Found Anti-atherosclerotic diaryl compounds
GB8921792D0 (en) 1989-09-27 1989-11-08 May & Baker Ltd New compositions of matter
AU6659090A (en) 1989-11-16 1991-06-13 Warner-Lambert Company Acat inhibitors
HU215847B (hu) 1989-11-22 1999-04-28 Janssen Pharmaceutica N.V. Eljárás N-fenil-piperazinacetamid-származékot tartalmazó, a véráramlás helyreállításakor bekövetkező károsodás megelőzésére vagy csökkentésére alkalmas gyógyászati készítmények és (1)-(-)-N-fenil-piperazinacetamid-származékok előállítására
US5106873A (en) 1990-06-26 1992-04-21 Warner-Lambert Company ACAT inhibitors
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JP2842147B2 (ja) * 1992-05-26 1998-12-24 大正製薬株式会社 Ａｃａｔ阻害剤
US6133326A (en) 1994-08-31 2000-10-17 Pfizer Inc Compositions and methods for decreasing sebum production
AU3577995A (en) 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
JP2004256473A (ja) * 2003-02-27 2004-09-16 Ono Pharmaceut Co Ltd エラスターゼ阻害活性を有する１，３，４−オキサジアゾール誘導体
RU2342930C2 (ru) 2003-10-09 2009-01-10 Уорнер-Ламберт Компани Ллс Фармацевтические композиции, содержащие малонамидные производные для уменьшения продукции кожного сала
US7163944B2 (en) * 2004-01-26 2007-01-16 Kowa Co., Ltd. Cyclic diamine compound and pharmaceutical containing the same
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
FR2920774B1 (fr) 2007-09-06 2009-10-30 Galderma Res & Dev Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant
FR2920769B1 (fr) 2007-09-06 2009-10-30 Galderma Res & Dev Nouveaux derives de n-phenyl acetamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant
FR2946346B1 (fr) * 2009-06-05 2011-05-20 Galderma Res & Dev Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
FR2946341B1 (fr) * 2009-06-05 2011-06-24 Galderma Res & Dev Nouveaux derives de n-phenyl acetamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.

Also Published As

Publication number Publication date
WO2010097464A1 (fr) 2010-09-02
US20120021017A1 (en) 2012-01-26
EP2401259A1 (fr) 2012-01-04
CA2751327A1 (fr) 2010-09-02
FR2946340A1 (fr) 2010-12-10
JP2012518675A (ja) 2012-08-16
US8420682B2 (en) 2013-04-16

Similar Documents

Publication Publication Date Title
MA32876B1 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
EP2210608A4 (fr) Composition pharmaceutique contenant des cellules-souches mésenchymateuses humaines
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EP2066785A4 (fr) Cultures bacteriennes et compositions contenant des cultures bacteriennes
EP2401264A4 (fr) Oligomères peptoïdes, compositions pharmaceutiques et leurs procédés d'utilisations
EP2474522A4 (fr) Agomélatine et compositions pharmaceutiques la contenant
IL206553A (en) Immunoassays are targeted to cells expressing CD138, medicinal preparations and their containing kits and uses
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
FR2961814B1 (fr) Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
EP2117523A4 (fr) Inhibiteurs de l'activité de akt
EP2131848A4 (fr) Compositions et methodes de potentialisation de l'activite de molecules biologiquement actives
ATE508732T1 (de) Kosmetischer wirkstoff aus argininferrulat und einem mikroalgen-extrakt und seine verwendungen
FR2912746B1 (fr) Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
BRPI0813897A2 (pt) Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, seqüência de nucleotídeos.
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
EP2252669A4 (fr) Composition de type azéotrope de 1,1,1-trifluoro-3-chloropropène et d acétate de méthyle
MA28370A1 (fr) Derives de alkylpiperazine-et alkylhomopiperazine-carboxylates, leur preparation et leur application en tant qu'inhibiteurs de l'enzyme faah
FR2898493B1 (fr) Compositions cosmetiques, pharmaceutiques, alimentaires et veterinaires dont l'action d'activation de genes de type sirtuin permet de retarder le vieillissement des mammiferes et ses effets nefastes
EP2376101A4 (fr) EFFECTEURS DE LA ß-ARRESTINE, COMPOSITIONS EN CONTENANT ET LEURS PROCÉDÉS D'UTILISATION
FR2946341B1 (fr) Nouveaux derives de n-phenyl acetamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
FR2949782B1 (fr) Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
EP2484349A4 (fr) Inhibiteur de l'activité héparanase, agent améliorant les rides le contenant, et composition pharmaceutique
FR2920774B1 (fr) Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant
FR2920769B1 (fr) Nouveaux derives de n-phenyl acetamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant
EP2029150A4 (fr) Extrait de plantes et composition le contenant

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20150227